Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina

Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Máspero, Jorge, Angles, María Valeria, Ardusso, Ledit, Brancciforte, Milagros, Castro, Carla, Cruz Iturrieta, Carmen, Chouela, Ezequiel, De Gennaro, Mónica Silvia, Fernández Bussy, Ramón, Galimberti, María Laura, Galimberti, Ricardo Luis, Gattolin, Gabriel, Luna, Paula Carolina, Magariños, Gabriel, Marini, Mariano Gabriel, Maskin, Matías, Plafnik, Romina, Raimondo, Nélida, Russo, Juan Pedro, Sevinsky, Luis, Stringa, Matías Federico
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2020
Materias:
dermatitis, atopic
biological products
antibodies, monoclonal
dermatitis atópica
productos biológicos
anticuerpos monoclonales
dermatite atópica
produtos biológicos
anticorpos monoclonais
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/27845
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
Descripción
Sumario:Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the clinical response of a group of patients from Argentina with severe AD and insufficient response and/or toxicity to CSTs who were treated with dupilumab before commercial availability was analyzed. EASI, SCORAD, DLQI scales and analog visual scales of pruritus and sleep were evaluated, during a median follow-up of 189 days. In addition, the incidence of adverse events was analyzed. Results: 20 patients (13 male) were included; median age: 37.5 years; median AD evolution: 20 years; atopic comorbidity: 70%. 100% had received systemic corticosteroids (serious complications: 20%). Main reasons for discontinuation of CSTs were lack of efficacy and occurrence of adverse events. All scores were significantly and steadily reduced, with identifiable clinical response at the second month of treatment. At the end of the follow-up, only 3 patients required concomitant systemic immunosuppressive treatment. Dupilumab was well tolerated, with mild and controllable adverse events. Discussion: Dupilumab is the only biological agent with high efficacy demonstrated in clinical and observational studies. In this case series, its effectiveness was confirmed in difficult-to-treat patients with severe AD and inadequate response to CSTs. The safety profile was favorable and consistent.

Ejemplares similares